Last reviewed · How we verify
BT-114143
At a glance
| Generic name | BT-114143 |
|---|---|
| Sponsor | ScinnoHub Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding (PHASE1)
- Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA） (PHASE2)
- Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT-114143 CI brief — competitive landscape report
- BT-114143 updates RSS · CI watch RSS
- ScinnoHub Pharmaceutical Co., Ltd. portfolio CI